172 related articles for article (PubMed ID: 38192537)
21. An Engineered IL15 Cytokine Mutein Fused to an Anti-PD1 Improves Intratumoral T-cell Function and Antitumor Immunity.
Xu Y; Carrascosa LC; Yeung YA; Chu ML; Yang W; Djuretic I; Pappas DC; Zeytounian J; Ge Z; de Ruiter V; Starbeck-Miller GR; Patterson J; Rigas D; Chen SH; Kraynov E; Boor PP; Noordam L; Doukas M; Tsao D; Ijzermans JN; Guo J; Grünhagen DJ; Erdmann J; Verheij J; van Royen ME; Doornebosch PG; Feldman R; Park T; Mahmoudi S; Dorywalska M; Ni I; Chin SM; Mistry T; Mosyak L; Lin L; Ching KA; Lindquist KC; Ji C; Londono LM; Kuang B; Rickert R; Kwekkeboom J; Sprengers D; Huang TH; Chaparro-Riggers J
Cancer Immunol Res; 2021 Oct; 9(10):1141-1157. PubMed ID: 34376502
[TBL] [Abstract][Full Text] [Related]
22. A2A Receptor Contributes to Tumor Progression in P2X7 Null Mice.
De Marchi E; Pegoraro A; Turiello R; Di Virgilio F; Morello S; Adinolfi E
Front Cell Dev Biol; 2022; 10():876510. PubMed ID: 35663396
[TBL] [Abstract][Full Text] [Related]
23. Caffeine-folic acid-loaded-chitosan nanoparticles combined with methotrexate as a novel HepG2 immunotherapy targeting adenosine A2A receptor downstream cascade.
Hamed A; Ghareeb D; Mohamed TM; Hamed M; Nofal MS; Gaber M
BMC Complement Med Ther; 2023 Oct; 23(1):384. PubMed ID: 37891562
[TBL] [Abstract][Full Text] [Related]
24. A
Kjaergaard J; Hatfield S; Jones G; Ohta A; Sitkovsky M
J Immunol; 2018 Jul; 201(2):782-791. PubMed ID: 29802128
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic Effects of Anti-PD1 Immunotherapy on Hepatocellular Carcinoma Under Administration of Tacrolimus.
Hsu YC; Chen CH; Huang HF; Lee YT; Wu MC; Su CW; Chou HC; Wang LF; Lee HS; Lin SW; Hsu PN; Wu YM; Sheu JC; Weng MT
Transplantation; 2023 Jul; 107(7):1492-1501. PubMed ID: 36380450
[TBL] [Abstract][Full Text] [Related]
26. [Blocking Adenosine/A2AR Pathway for Cancer Therapy].
Liu J; Shi Y; Liu X; Zhang D; Bai Y; Xu Y; Wang M
Zhongguo Fei Ai Za Zhi; 2022 Jul; 25(7):460-467. PubMed ID: 35899442
[TBL] [Abstract][Full Text] [Related]
27. Disruption of adenosine 2A receptor improves the anti-tumor function of anti-mesothelin CAR T cells both in vitro and in vivo.
Liu G; Zhang Q; Liu G; Li D; Zhang L; Gu Z; Tian H; Zhang Y; Tian X
Exp Cell Res; 2021 Dec; 409(1):112886. PubMed ID: 34673000
[TBL] [Abstract][Full Text] [Related]
28. Genetic and pharmacological targeting of A2a receptor improves function of anti-mesothelin CAR T cells.
Masoumi E; Jafarzadeh L; Mirzaei HR; Alishah K; Fallah-Mehrjardi K; Rostamian H; Khakpoor-Koosheh M; Meshkani R; Noorbakhsh F; Hadjati J
J Exp Clin Cancer Res; 2020 Mar; 39(1):49. PubMed ID: 32151275
[TBL] [Abstract][Full Text] [Related]
29. Cabozantinib Enhances Anti-PD1 Activity and Elicits a Neutrophil-Based Immune Response in Hepatocellular Carcinoma.
Esteban-Fabró R; Willoughby CE; Piqué-Gili M; Montironi C; Abril-Fornaguera J; Peix J; Torrens L; Mesropian A; Balaseviciute U; Miró-Mur F; Mazzaferro V; Pinyol R; Llovet JM
Clin Cancer Res; 2022 Jun; 28(11):2449-2460. PubMed ID: 35302601
[TBL] [Abstract][Full Text] [Related]
30. A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2a Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor Microenvironment.
Mediavilla-Varela M; Castro J; Chiappori A; Noyes D; Hernandez DC; Allard B; Stagg J; Antonia SJ
Neoplasia; 2017 Jul; 19(7):530-536. PubMed ID: 28582704
[TBL] [Abstract][Full Text] [Related]
31. Adenosine 2a Receptor Signal Blockade of Murine Autoimmune Arthritis via Inhibition of Pathogenic Germinal Center-Follicular Helper T Cells.
Schmiel SE; Kalekar LA; Zhang N; Blankespoor TW; Robinson LJ; Mueller DL
Arthritis Rheumatol; 2019 May; 71(5):773-783. PubMed ID: 30516351
[TBL] [Abstract][Full Text] [Related]
32. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
[TBL] [Abstract][Full Text] [Related]
33. TOX promotes the exhaustion of antitumor CD8
Wang X; He Q; Shen H; Xia A; Tian W; Yu W; Sun B
J Hepatol; 2019 Oct; 71(4):731-741. PubMed ID: 31173813
[TBL] [Abstract][Full Text] [Related]
34. Dual roles of the adenosine A2a receptor in autoimmune neuroinflammation.
Ingwersen J; Wingerath B; Graf J; Lepka K; Hofrichter M; Schröter F; Wedekind F; Bauer A; Schrader J; Hartung HP; Prozorovski T; Aktas O
J Neuroinflammation; 2016 Feb; 13():48. PubMed ID: 26920550
[TBL] [Abstract][Full Text] [Related]
35. A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy.
Leone RD; Lo YC; Powell JD
Comput Struct Biotechnol J; 2015; 13():265-72. PubMed ID: 25941561
[TBL] [Abstract][Full Text] [Related]
36. Activation of microglial cells triggers a release of brain-derived neurotrophic factor (BDNF) inducing their proliferation in an adenosine A2A receptor-dependent manner: A2A receptor blockade prevents BDNF release and proliferation of microglia.
Gomes C; Ferreira R; George J; Sanches R; Rodrigues DI; Gonçalves N; Cunha RA
J Neuroinflammation; 2013 Jan; 10():16. PubMed ID: 23363775
[TBL] [Abstract][Full Text] [Related]
37. Blockade of adenosine A
Li XC; Hong FF; Tu YJ; Li YA; Ma CY; Yu CY; Fang L; Chen JY; Li ZL; Bao SJ; Zhang ZL; Ying HY; Gyabaah AT; Hu SY; Shao GH; Cai XH
Exp Neurol; 2022 Apr; 350():113929. PubMed ID: 34813840
[TBL] [Abstract][Full Text] [Related]
38. Reprogramming Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti-PD1 Therapy.
Chen J; Amoozgar Z; Liu X; Aoki S; Liu Z; Shin S; Matsui A; Pu Z; Lei PJ; Datta M; Zhu L; Ruan Z; Shi L; Staiculescu D; Inoue K; Munn LL; Fukumura D; Huang P; Bardeesy N; Ho WJ; Jain RK; Duda DG
bioRxiv; 2023 Jan; ():. PubMed ID: 36747853
[TBL] [Abstract][Full Text] [Related]
39. Baicalin attenuates chronic hypoxia-induced pulmonary hypertension via adenosine A
Huang X; Wu P; Huang F; Xu M; Chen M; Huang K; Li GP; Xu M; Yao D; Wang L
J Biomed Sci; 2017 Aug; 24(1):52. PubMed ID: 28774332
[TBL] [Abstract][Full Text] [Related]
40. Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1.
Thomas S; Kuncheria L; Roulstone V; Kyula JN; Mansfield D; Bommareddy PK; Smith H; Kaufman HL; Harrington KJ; Coffin RS
J Immunother Cancer; 2019 Aug; 7(1):214. PubMed ID: 31399043
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
